Dynavax To Seek Experienced Vaccines Partner To Commercialize Heplisav
This article was originally published in The Pink Sheet Daily
Executive Summary
The company reports positive Phase III data for the hepatitis B vaccine showing 98.5% seroprotection after two doses.